This document presents a case study of a 49-year-old male who presented with hypercalcemia. His investigations revealed a calcium level of 3.2 mmol/L. He had symptoms of abdominal discomfort, fatigue, and increased thirst. His examination and tests ruled out various potential causes of hypercalcemia. He was found to have elevated PTH, consistent with primary hyperparathyroidism. He was treated with IV fluids and bisphosphonates and will likely require parathyroidectomy surgery to address the underlying cause of his hypercalcemia.
Hypercalcemia was causing the patient's acute renal failure. Treatment for hypercalcemia included intravenous fluids, furosemide, steroids, bisphosphonates, and dialysis which lowered the calcium levels and improved renal function. The underlying cause of hypercalcemia could not be determined after extensive testing, but was likely a malignancy given the persistent pancytopenia. Hypercalcemia can directly damage the kidneys by decreasing medullary osmolality and inducing nephrogenic diabetes insipidus, nephrolithiasis, and renal tubular acidosis. It also causes vasoconstriction and activation of the calcium-sensing receptor which stimulates renin release and worsens volume
Hypercalcemia is elevated calcium levels in the blood. Normal calcium levels are 2.12-2.65 mmol/L. It is uncommon, affecting 4 in 100,000 people per year, and more common in females ages 50-60. Signs and symptoms include bone pain, kidney stones, constipation, fatigue, and renal failure. Causes include primary hyperparathyroidism, malignancy, certain drugs, and granulomatous diseases. Diagnosis involves blood and imaging tests. Treatment consists of IV fluids, correcting electrolyte imbalances, diuretics, treating the underlying cause, bisphosphonates, steroids, and calcitonin. Untreated severe hypercalcemia can lead to osteop
Hypercalcemia is commonly caused by primary hyperparathyroidism or malignancy. It can be life-threatening in severe cases. Diagnosis involves measuring serum calcium, PTH, and assessing for underlying causes. Treatment depends on the underlying condition but may involve surgery for hyperparathyroidism or addressing the malignancy. Complications can impact the kidneys, GI tract, cardiovascular system, muscles and bones.
This document defines hypercalcemia and discusses its causes, evaluation, clinical presentation, and management. The main causes are parathyroid hormone dependent (primary hyperparathyroidism, tertiary hyperparathyroidism) and independent (malignancy, vitamin D related, endocrinopathies). Evaluation involves history, exam, and labs. Acute management is rehydration and medications to increase calcium excretion. Long term management depends on the underlying cause and may involve surgery, bisphosphonates, glucocorticoids, or ketoconazole.
Approach to patient with hypo/hyper calcaemiaNassr ALBarhi
This document discusses calcium homeostasis and disorders of calcium metabolism. It begins by describing the functions of calcium in the body and where calcium is stored. It then discusses calcium regulation by parathyroid hormone, vitamin D, and calcitonin. Causes, signs and symptoms, and treatment approaches for hypercalcemia and hypocalcemia are reviewed. The key points are that calcium levels are tightly controlled by hormones to maintain levels between 2.25-2.62 mmol/L and that disorders can result from excess or deficiencies of these regulating hormones.
This document presents the case of an 80-year-old woman with metastatic breast cancer and a history of parathyroid adenoma who presented with vomiting, diarrhea, fatigue and severe abdominal pain. Initial workup found hypercalcemia likely due to both bony metastases and primary hyperparathyroidism. She was aggressively rehydrated and further testing found suppressed PTH levels, supporting the diagnosis of hypercalcemia secondary to bony metastatic disease rather than parathyroid adenoma. Her calcium levels responded well to intravenous fluids and she was managed conservatively.
This document presents a case study of a 41-year-old woman diagnosed with hypercalcemia caused by milk alkali syndrome. She was brought to the emergency department with nausea, vomiting, and altered mental status. Tests found her blood calcium level to be very high. Her history of consuming large amounts of antacids containing calcium and sodium bicarbonate led to the diagnosis of milk alkali syndrome. Milk alkali syndrome occurs when excessive oral intake of calcium and alkali impairs the kidney's ability to excrete calcium, resulting in hypercalcemia. The document then provides background information on calcium regulation and the various causes, symptoms, diagnostic evaluation, and treatment approaches for hypercalcemia.
This document discusses calcium homeostasis and hypercalcemia. It notes that calcium is critical for many physiological functions and is mainly stored in bones. Hypercalcemia can be caused by primary hyperparathyroidism, vitamin D excess, certain malignancies, and other conditions. The diagnostic approach involves distinguishing between hyperparathyroidism and hypercalcemia of malignancy based on lab tests. Treatment focuses on rehydration, increasing calciuresis, and decreasing bone resorption or intestinal calcium absorption using medications like calcitonin, bisphosphonates, glucocorticoids, or dialysis depending on the severity of hypercalcemia.
Hypercalcemia was causing the patient's acute renal failure. Treatment for hypercalcemia included intravenous fluids, furosemide, steroids, bisphosphonates, and dialysis which lowered the calcium levels and improved renal function. The underlying cause of hypercalcemia could not be determined after extensive testing, but was likely a malignancy given the persistent pancytopenia. Hypercalcemia can directly damage the kidneys by decreasing medullary osmolality and inducing nephrogenic diabetes insipidus, nephrolithiasis, and renal tubular acidosis. It also causes vasoconstriction and activation of the calcium-sensing receptor which stimulates renin release and worsens volume
Hypercalcemia is elevated calcium levels in the blood. Normal calcium levels are 2.12-2.65 mmol/L. It is uncommon, affecting 4 in 100,000 people per year, and more common in females ages 50-60. Signs and symptoms include bone pain, kidney stones, constipation, fatigue, and renal failure. Causes include primary hyperparathyroidism, malignancy, certain drugs, and granulomatous diseases. Diagnosis involves blood and imaging tests. Treatment consists of IV fluids, correcting electrolyte imbalances, diuretics, treating the underlying cause, bisphosphonates, steroids, and calcitonin. Untreated severe hypercalcemia can lead to osteop
Hypercalcemia is commonly caused by primary hyperparathyroidism or malignancy. It can be life-threatening in severe cases. Diagnosis involves measuring serum calcium, PTH, and assessing for underlying causes. Treatment depends on the underlying condition but may involve surgery for hyperparathyroidism or addressing the malignancy. Complications can impact the kidneys, GI tract, cardiovascular system, muscles and bones.
This document defines hypercalcemia and discusses its causes, evaluation, clinical presentation, and management. The main causes are parathyroid hormone dependent (primary hyperparathyroidism, tertiary hyperparathyroidism) and independent (malignancy, vitamin D related, endocrinopathies). Evaluation involves history, exam, and labs. Acute management is rehydration and medications to increase calcium excretion. Long term management depends on the underlying cause and may involve surgery, bisphosphonates, glucocorticoids, or ketoconazole.
Approach to patient with hypo/hyper calcaemiaNassr ALBarhi
This document discusses calcium homeostasis and disorders of calcium metabolism. It begins by describing the functions of calcium in the body and where calcium is stored. It then discusses calcium regulation by parathyroid hormone, vitamin D, and calcitonin. Causes, signs and symptoms, and treatment approaches for hypercalcemia and hypocalcemia are reviewed. The key points are that calcium levels are tightly controlled by hormones to maintain levels between 2.25-2.62 mmol/L and that disorders can result from excess or deficiencies of these regulating hormones.
This document presents the case of an 80-year-old woman with metastatic breast cancer and a history of parathyroid adenoma who presented with vomiting, diarrhea, fatigue and severe abdominal pain. Initial workup found hypercalcemia likely due to both bony metastases and primary hyperparathyroidism. She was aggressively rehydrated and further testing found suppressed PTH levels, supporting the diagnosis of hypercalcemia secondary to bony metastatic disease rather than parathyroid adenoma. Her calcium levels responded well to intravenous fluids and she was managed conservatively.
This document presents a case study of a 41-year-old woman diagnosed with hypercalcemia caused by milk alkali syndrome. She was brought to the emergency department with nausea, vomiting, and altered mental status. Tests found her blood calcium level to be very high. Her history of consuming large amounts of antacids containing calcium and sodium bicarbonate led to the diagnosis of milk alkali syndrome. Milk alkali syndrome occurs when excessive oral intake of calcium and alkali impairs the kidney's ability to excrete calcium, resulting in hypercalcemia. The document then provides background information on calcium regulation and the various causes, symptoms, diagnostic evaluation, and treatment approaches for hypercalcemia.
This document discusses calcium homeostasis and hypercalcemia. It notes that calcium is critical for many physiological functions and is mainly stored in bones. Hypercalcemia can be caused by primary hyperparathyroidism, vitamin D excess, certain malignancies, and other conditions. The diagnostic approach involves distinguishing between hyperparathyroidism and hypercalcemia of malignancy based on lab tests. Treatment focuses on rehydration, increasing calciuresis, and decreasing bone resorption or intestinal calcium absorption using medications like calcitonin, bisphosphonates, glucocorticoids, or dialysis depending on the severity of hypercalcemia.
This document discusses hypercalcemia, which is defined as a serum calcium level above 10.5 mg/dl. It outlines the causes of hypercalcemia including primary hyperparathyroidism, certain cancers, and excessive vitamin D or calcium supplementation. Signs and symptoms are noted such as abdominal pain, nausea, weakness and cardiac issues. Diagnostic testing including PTH, calcium, and phosphate levels as well as imaging are covered. Treatment focuses on rehydration, bisphosphonates, glucocorticoids, calcitonin, surgery if needed, and addressing the underlying cause. Complications of untreated hypercalcemia include osteoporosis, kidney stones, and kidney failure.
This document discusses hypocalcemia, beginning with an overview of calcium homeostasis. It then covers the etiology of low and high parathyroid hormone levels as causes of hypocalcemia. Specific conditions that can cause hypocalcemia like post-thyroidectomy, autoimmune disorders, chronic kidney disease, and vitamin D deficiency are described. Other potential causes like pseudohypocalcemia, acid-base abnormalities, pancreatitis, and sepsis are also reviewed. The clinical features, evaluation, and management of hypocalcemia are summarized.
The document discusses calcium homeostasis and hypercalcemia. It provides details on:
- Calcium distribution in the body, with 99% located in bones and teeth.
- Intestinal and renal handling of calcium and the roles of TRPV5 channel and calbindin D28k protein.
- Causes of hypercalcemia including primary hyperparathyroidism, malignancy, and vitamin D excess.
- Presentation of hypercalcemia ranging from asymptomatic to severe symptoms like confusion.
- Workup and treatment of hypercalcemia depending on its underlying cause and severity.
This document summarizes parathyroid gland anatomy and physiology and various types of hyperparathyroidism. It discusses the role of parathyroid hormone in calcium homeostasis, causes of primary, secondary, and tertiary hyperparathyroidism, associated symptoms and complications, diagnostic testing, treatment options including medication and surgery, and other related conditions like familial benign hypercalcemia and hypercalcemia of malignancy.
This document discusses magnesium disorders and hypomagnesemia. It begins by providing background on magnesium, including where it is stored in the body and its many functions. It then discusses the causes, clinical manifestations, diagnosis, and treatment of hypomagnesemia. Hypomagnesemia can be caused by renal magnesium wasting due to drugs, diseases, or genetic disorders, or by extrarenal losses from poor nutrition, malabsorption, diarrhea, or sweat losses. Symptoms affect the cardiovascular, neuromuscular, skeletal, and central nervous systems. Treatment involves identifying and addressing the underlying cause, as well as oral or parenteral magnesium supplementation.
Hypercalcaemia is a common disorder we doctors from all faculties face in day to day clinical practice. This was a presentation done by me to give you an update regarding hypercalcaemia and it's management.
The document discusses potassium metabolism and disorders of potassium levels. It covers:
1) Normal potassium metabolism and regulation by the kidneys, factors that influence renal secretion/excretion.
2) Causes and pathophysiology of hypokalemia and hyperkalemia, including excessive renal/gastrointestinal loss or intake, shifts between intracellular/extracellular fluid.
3) Effects of abnormal potassium levels on neuromuscular and cardiac function, including changes in membrane potential and electrical activity.
This document provides an overview of hypocalcemia, including:
- Causes of hypocalcemia such as hypoparathyroidism, vitamin D deficiency, renal failure, sepsis
- Symptoms of hypocalcemia including neurological symptoms, muscle spasms, cardiac issues
- Diagnosis and treatment of hypocalcemia including IV calcium supplementation and monitoring calcium levels
- Etiologies of hypocalcemia like hungry bone syndrome, acute pancreatitis, medications that can cause hypocalcemia
- Overview of calcium regulation in the kidney and genes involved
This document discusses calcium homeostasis and hypercalcemia. It explains that blood calcium levels are tightly regulated by the parathyroid hormone (PTH), vitamin D, gut, bone and kidneys. The main causes of hypercalcemia are primary hyperparathyroidism, malignancy-related hypercalcemia from bone metastases, and hypervitaminosis D from excessive vitamin D intake or production. The document provides details on the pathophysiology, clinical evaluation and management of hypercalcemia.
1) Primary hyperaldosteronism, also known as Conn's syndrome, is characterized by excessive secretion of the hormone aldosterone from the adrenal glands, causing increased sodium retention and potassium excretion.
2) It can be caused by an aldosterone-producing adenoma, idiopathic bilateral adrenal hyperplasia, or adrenal carcinoma. Aldosterone-producing adenomas account for 65-70% of cases.
3) Symptoms include hypertension, hypokalemia, headaches, and muscle weakness. Diagnostic tests include measuring aldosterone and renin levels, with an elevated aldosterone-to-renin ratio confirming the diagnosis. Treatment options include surgical removal of
This document discusses calcium metabolism and hypercalcemia. It covers normal calcium values, calcium types, metabolism, regulation by hormones like PTH and vitamin D, and the calcium sensing receptor. The main causes of hypercalcemia are primary hyperparathyroidism, malignancy-associated hypercalcemia, and granulomatous diseases. Symptoms range from none in mild cases to multi-organ involvement in severe cases. Diagnosis involves measuring corrected calcium and PTH levels. Treatment aims to lower calcium through hydration, calcitonin, bisphosphonates, glucocorticoids, calcimimetics, or dialysis depending on severity. Surgery in the form of parathyroidectomy may be indicated in
The pathogenesis of CKD-MBD is complex, involving disruptions in mineral homeostasis and hormone levels as kidney function declines. Key factors include hyperphosphatemia, decreased calcitriol levels, and hypocalcemia. This leads to elevated PTH levels as the parathyroid glands respond to low calcium and calcitriol. Over time, the parathyroid glands become resistant due to downregulation of receptors. Progressive CKD also impairs the kidneys' ability to regulate phosphate, exacerbating hyperphosphatemia and CKD-MBD.
This document discusses the approach to hypokalemia. It begins by covering the pathophysiology of potassium homeostasis and how small changes in potassium levels can have profound effects. It then discusses factors that can modify cellular potassium distribution like acid-base status, hormones, exercise and more. Treatment of hypokalemia involves decreasing potassium losses, replenishing stores, addressing any toxicities, and determining the underlying cause. Oral and intravenous potassium replacement is discussed as well as monitoring requirements and administration rates.
This document discusses calcium homeostasis and hypercalcemia. It notes that approximately 99% of calcium in the body is stored in bones and teeth, with the remaining 1% distributed in the extracellular fluid, intracellular fluid, and soft tissues. Hypercalcemia is defined as a serum calcium level above 10.5 mg/dL. Causes include primary hyperparathyroidism in about 50% of cases of hypercalcemia, as well as malignancy, vitamin D toxicity, hyperthyroidism, and certain genetic conditions. Symptoms range from being mild or absent with mild increases in calcium to severe symptoms like confusion and coma with rapid or large rises in calcium levels.
This document discusses two cases of pediatric hypocalcemia. The first case involves an 8-year-old girl with vomiting, twitching, and low calcium and vitamin D levels. Her PTH level is high, suggesting pseudohypoparathyroidism type 2B. The second case involves a 1-month-old with abnormal movements, dysmorphic features, a ventricular septal defect, and DiGeorge syndrome based on testing. The document then reviews causes, evaluations, and treatments for hypocalcemia in children.
Hypophosphatemia is a condition defined by a serum phosphorus level lower than 2.7 mg/dL, which can be caused by insufficient phosphorus intake, increased phosphorus excretion, or intracellular shifts. Symptoms include decreased cardiac and respiratory function, weakness, impaired reflexes, bone abnormalities, irritability, and bleeding issues. Treatment involves monitoring for symptoms, discontinuing contributing medications, supplementing with phosphorus and vitamin D orally or intravenously, careful movement to prevent fractures, and dietary adjustments to intake phosphorus-rich and limit calcium-rich foods.
Hypocalcemia has various presentations and can lead to significant morbidity if left untreated. The most common cause is hypoalbuminemia from conditions like cirrhosis or malnutrition that lower serum calcium levels. Other potential causes include vitamin D deficiency, parathyroid issues, medications, and critical illnesses like sepsis. Treatment involves identifying and addressing the underlying cause, as well as replacing calcium, often intravenously, to resolve symptoms and normalize calcium levels. Calcium levels must be closely monitored during treatment until stabilized.
The document is a clinical skills guide that was created by the author for a competition. It contains instructions for over 20 different clinical skills including hand washing, taking vital signs, blood pressure measurement, various types of injections, and other procedures. The guide provides step-by-step explanations of how to properly perform each skill for assessment in the competition.
This patient had a history of intestinal resection and was admitted for recurrent fractures. On examination, he had positive Chvostek's and Trousseau's signs. Laboratory results showed low serum calcium and high phosphate levels. He was diagnosed with hypoparathyroidism secondary to intestinal resection and treated with calcium and vitamin D supplementation.
This document discusses hypercalcemia, which is defined as a serum calcium level above 10.5 mg/dl. It outlines the causes of hypercalcemia including primary hyperparathyroidism, certain cancers, and excessive vitamin D or calcium supplementation. Signs and symptoms are noted such as abdominal pain, nausea, weakness and cardiac issues. Diagnostic testing including PTH, calcium, and phosphate levels as well as imaging are covered. Treatment focuses on rehydration, bisphosphonates, glucocorticoids, calcitonin, surgery if needed, and addressing the underlying cause. Complications of untreated hypercalcemia include osteoporosis, kidney stones, and kidney failure.
This document discusses hypocalcemia, beginning with an overview of calcium homeostasis. It then covers the etiology of low and high parathyroid hormone levels as causes of hypocalcemia. Specific conditions that can cause hypocalcemia like post-thyroidectomy, autoimmune disorders, chronic kidney disease, and vitamin D deficiency are described. Other potential causes like pseudohypocalcemia, acid-base abnormalities, pancreatitis, and sepsis are also reviewed. The clinical features, evaluation, and management of hypocalcemia are summarized.
The document discusses calcium homeostasis and hypercalcemia. It provides details on:
- Calcium distribution in the body, with 99% located in bones and teeth.
- Intestinal and renal handling of calcium and the roles of TRPV5 channel and calbindin D28k protein.
- Causes of hypercalcemia including primary hyperparathyroidism, malignancy, and vitamin D excess.
- Presentation of hypercalcemia ranging from asymptomatic to severe symptoms like confusion.
- Workup and treatment of hypercalcemia depending on its underlying cause and severity.
This document summarizes parathyroid gland anatomy and physiology and various types of hyperparathyroidism. It discusses the role of parathyroid hormone in calcium homeostasis, causes of primary, secondary, and tertiary hyperparathyroidism, associated symptoms and complications, diagnostic testing, treatment options including medication and surgery, and other related conditions like familial benign hypercalcemia and hypercalcemia of malignancy.
This document discusses magnesium disorders and hypomagnesemia. It begins by providing background on magnesium, including where it is stored in the body and its many functions. It then discusses the causes, clinical manifestations, diagnosis, and treatment of hypomagnesemia. Hypomagnesemia can be caused by renal magnesium wasting due to drugs, diseases, or genetic disorders, or by extrarenal losses from poor nutrition, malabsorption, diarrhea, or sweat losses. Symptoms affect the cardiovascular, neuromuscular, skeletal, and central nervous systems. Treatment involves identifying and addressing the underlying cause, as well as oral or parenteral magnesium supplementation.
Hypercalcaemia is a common disorder we doctors from all faculties face in day to day clinical practice. This was a presentation done by me to give you an update regarding hypercalcaemia and it's management.
The document discusses potassium metabolism and disorders of potassium levels. It covers:
1) Normal potassium metabolism and regulation by the kidneys, factors that influence renal secretion/excretion.
2) Causes and pathophysiology of hypokalemia and hyperkalemia, including excessive renal/gastrointestinal loss or intake, shifts between intracellular/extracellular fluid.
3) Effects of abnormal potassium levels on neuromuscular and cardiac function, including changes in membrane potential and electrical activity.
This document provides an overview of hypocalcemia, including:
- Causes of hypocalcemia such as hypoparathyroidism, vitamin D deficiency, renal failure, sepsis
- Symptoms of hypocalcemia including neurological symptoms, muscle spasms, cardiac issues
- Diagnosis and treatment of hypocalcemia including IV calcium supplementation and monitoring calcium levels
- Etiologies of hypocalcemia like hungry bone syndrome, acute pancreatitis, medications that can cause hypocalcemia
- Overview of calcium regulation in the kidney and genes involved
This document discusses calcium homeostasis and hypercalcemia. It explains that blood calcium levels are tightly regulated by the parathyroid hormone (PTH), vitamin D, gut, bone and kidneys. The main causes of hypercalcemia are primary hyperparathyroidism, malignancy-related hypercalcemia from bone metastases, and hypervitaminosis D from excessive vitamin D intake or production. The document provides details on the pathophysiology, clinical evaluation and management of hypercalcemia.
1) Primary hyperaldosteronism, also known as Conn's syndrome, is characterized by excessive secretion of the hormone aldosterone from the adrenal glands, causing increased sodium retention and potassium excretion.
2) It can be caused by an aldosterone-producing adenoma, idiopathic bilateral adrenal hyperplasia, or adrenal carcinoma. Aldosterone-producing adenomas account for 65-70% of cases.
3) Symptoms include hypertension, hypokalemia, headaches, and muscle weakness. Diagnostic tests include measuring aldosterone and renin levels, with an elevated aldosterone-to-renin ratio confirming the diagnosis. Treatment options include surgical removal of
This document discusses calcium metabolism and hypercalcemia. It covers normal calcium values, calcium types, metabolism, regulation by hormones like PTH and vitamin D, and the calcium sensing receptor. The main causes of hypercalcemia are primary hyperparathyroidism, malignancy-associated hypercalcemia, and granulomatous diseases. Symptoms range from none in mild cases to multi-organ involvement in severe cases. Diagnosis involves measuring corrected calcium and PTH levels. Treatment aims to lower calcium through hydration, calcitonin, bisphosphonates, glucocorticoids, calcimimetics, or dialysis depending on severity. Surgery in the form of parathyroidectomy may be indicated in
The pathogenesis of CKD-MBD is complex, involving disruptions in mineral homeostasis and hormone levels as kidney function declines. Key factors include hyperphosphatemia, decreased calcitriol levels, and hypocalcemia. This leads to elevated PTH levels as the parathyroid glands respond to low calcium and calcitriol. Over time, the parathyroid glands become resistant due to downregulation of receptors. Progressive CKD also impairs the kidneys' ability to regulate phosphate, exacerbating hyperphosphatemia and CKD-MBD.
This document discusses the approach to hypokalemia. It begins by covering the pathophysiology of potassium homeostasis and how small changes in potassium levels can have profound effects. It then discusses factors that can modify cellular potassium distribution like acid-base status, hormones, exercise and more. Treatment of hypokalemia involves decreasing potassium losses, replenishing stores, addressing any toxicities, and determining the underlying cause. Oral and intravenous potassium replacement is discussed as well as monitoring requirements and administration rates.
This document discusses calcium homeostasis and hypercalcemia. It notes that approximately 99% of calcium in the body is stored in bones and teeth, with the remaining 1% distributed in the extracellular fluid, intracellular fluid, and soft tissues. Hypercalcemia is defined as a serum calcium level above 10.5 mg/dL. Causes include primary hyperparathyroidism in about 50% of cases of hypercalcemia, as well as malignancy, vitamin D toxicity, hyperthyroidism, and certain genetic conditions. Symptoms range from being mild or absent with mild increases in calcium to severe symptoms like confusion and coma with rapid or large rises in calcium levels.
This document discusses two cases of pediatric hypocalcemia. The first case involves an 8-year-old girl with vomiting, twitching, and low calcium and vitamin D levels. Her PTH level is high, suggesting pseudohypoparathyroidism type 2B. The second case involves a 1-month-old with abnormal movements, dysmorphic features, a ventricular septal defect, and DiGeorge syndrome based on testing. The document then reviews causes, evaluations, and treatments for hypocalcemia in children.
Hypophosphatemia is a condition defined by a serum phosphorus level lower than 2.7 mg/dL, which can be caused by insufficient phosphorus intake, increased phosphorus excretion, or intracellular shifts. Symptoms include decreased cardiac and respiratory function, weakness, impaired reflexes, bone abnormalities, irritability, and bleeding issues. Treatment involves monitoring for symptoms, discontinuing contributing medications, supplementing with phosphorus and vitamin D orally or intravenously, careful movement to prevent fractures, and dietary adjustments to intake phosphorus-rich and limit calcium-rich foods.
Hypocalcemia has various presentations and can lead to significant morbidity if left untreated. The most common cause is hypoalbuminemia from conditions like cirrhosis or malnutrition that lower serum calcium levels. Other potential causes include vitamin D deficiency, parathyroid issues, medications, and critical illnesses like sepsis. Treatment involves identifying and addressing the underlying cause, as well as replacing calcium, often intravenously, to resolve symptoms and normalize calcium levels. Calcium levels must be closely monitored during treatment until stabilized.
The document is a clinical skills guide that was created by the author for a competition. It contains instructions for over 20 different clinical skills including hand washing, taking vital signs, blood pressure measurement, various types of injections, and other procedures. The guide provides step-by-step explanations of how to properly perform each skill for assessment in the competition.
This patient had a history of intestinal resection and was admitted for recurrent fractures. On examination, he had positive Chvostek's and Trousseau's signs. Laboratory results showed low serum calcium and high phosphate levels. He was diagnosed with hypoparathyroidism secondary to intestinal resection and treated with calcium and vitamin D supplementation.
Hypercalcemia of malignancy (HCM) is the most common cause of hypercalcemia in hospitalized patients with cancer. PTH-rP is the leading cause of HCM and works through both humoral and local osteolytic mechanisms. RANKL plays a key role in bone resorption and is a potential treatment target. Optimal treatment requires addressing the underlying cause and degree of hypercalcemia and may include hydration, bisphosphonates, calcitonin, glucocorticoids, or denosumab which inhibits RANKL.
This document discusses malignant hypercalcaemia, which occurs in 10% of cancer patients and is caused by bone metastases or humoral factors released by tumour cells. It leads to high calcium levels in the blood (>3.0 mmol/L) and poor prognosis, with most patients dying within a year. The document outlines the physiology and clinical manifestations of hypercalcaemia and provides recommendations for investigations and management, including rehydration, calcium restriction, bisphosphonates, calcitonin, and targeting the underlying malignancy.
A 42-year-old man presented with fever, weight loss, cough, and other symptoms for two months. Examination found muscle wasting, elevated calcium levels, and diffuse lung infiltrates. This suggests primary hyperparathyroidism or malignancy as the likely causes, given the elevated calcium levels and imaging findings. Acute management may include IV fluids, bisphosphonates like pamidronate or zoledronate, calcitonin, or dialysis depending on calcium levels and symptoms.
The document summarizes thyroid function and disorders. It describes how thyroid stimulating hormone regulates thyroid hormone production and release. It also outlines the causes, symptoms, signs and treatments of hyperthyroidism and hypothyroidism. Specifically, it discusses Graves' disease, Hashimoto's thyroiditis, thyroid testing, and complications like thyroid storm.
This document provides guidance on performing a musculoskeletal examination of the joints. It describes the general principles of joint examination, including inspection, palpation, and assessing range of motion. Specific instructions are given for examining each major joint, including hands/wrists, elbows, shoulders, and assessment of surrounding structures like muscles. Inspection involves evaluating for swelling, deformities, and skin changes. Palpation feels for tenderness, swelling, temperature differences. Range of motion testing determines a joint's flexion, extension, abduction, adduction, and other movements.
1) A 10-year-old Labrador presented with PU/PD, lethargy, weight loss, and anorexia. Biochemistry revealed hypercalcemia.
2) Thoracic radiographs and ultrasound identified a cranial mediastinal mass. FNA was non-diagnostic but PCR suggested a mixed population of T-cells, consistent with mediastinal lymphoma.
3) The diagnosis was stage Vb mediastinal T-cell lymphoma, causing hypercalcemia of malignancy through PTHrP secretion and increased bone resorption. Treatment was palliative with steroids to reduce hypercalcemia and improve appetite.
This document discusses electrolyte imbalances, including sodium, potassium, chloride, calcium, and magnesium. For each electrolyte, it covers normal levels, causes of imbalances, signs and symptoms, diagnostic findings, and treatment approaches. Key points include the roles of electrolytes in nerve impulse transmission, acid-base balance, and other bodily functions. Major imbalances discussed are hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypomagnesemia, and hypermagnesemia.
1. An 8-year-old male presented with resistant rickets and bony deformities. Initial workup found hypocalcemia, hypophosphatemia, elevated alkaline phosphatase, and normal parathyroid hormone.
2. Further testing revealed proximal renal tubular acidosis, hypokalemia, and firm hepatomegaly. Wilson's disease was suspected and confirmed with elevated urinary copper levels.
3. The patient was diagnosed with Wilson's disease presenting as resistant rickets and proximal renal tubular acidosis. He was started on chelating agents and potassium citrate to treat the Wilson's disease and renal tubular acidosis respectively.
fluid & electrolyte imbalance in human body.pptDelphyVarghese
Fluid and electrolyte imbalance is a complex process that can occur with illness or injury as homeostasis is disrupted. Common imbalances include hypovolaemia or hypervolaemia due to fluid deficits or excesses, as well as abnormalities in sodium, potassium, and calcium levels. Care involves determining the underlying cause, monitoring for signs and symptoms of imbalance, and treating with fluid resuscitation or electrolyte replacement as needed.
This document discusses electrolyte disorders and their management. It covers water and sodium metabolism including hypo- and hypernatremia. It also discusses potassium disorders including hypo- and hyperkalemia. The key mechanisms and renal regulation of electrolytes are explained. Treatment approaches are outlined depending on the electrolyte abnormality and patient volume status. Symptoms, causes, and management strategies are provided for common electrolyte disorders.
The document discusses disorders of calcium metabolism. It presents two clinical scenarios: a 59-year-old woman with hypercalcemia found on labs during a routine visit, and a 9-year-old boy admitted to the emergency department with acute pancreatitis and hypocalcemia after falling off his bike. It then outlines topics like the different forms of calcium, calcium homeostasis, regulation of calcium metabolism by parathyroid hormone, vitamin D, and calcitonin, and disorders like hypercalcemia, hypocalcemia, hyperparathyroidism, and hypoparathyroidism.
A 45-year-old man presented with acute onset progressive weakness of all limbs. On examination, he had weakness predominantly affecting proximal muscles with depressed reflexes but intact sensation. Laboratory tests found hypokalemia with high urinary potassium excretion and metabolic alkalosis. Further evaluation found features consistent with Gitelman syndrome, a genetic disorder causing renal potassium wasting due to mutations impairing sodium-chloride transport. The patient was started on potassium-sparing diuretics and supplements to correct electrolyte abnormalities.
Acute renal failure (ARF) is defined as a rapid decline in kidney function over hours or days. It can be caused by decreased blood flow to the kidneys, damage or toxicity to the kidney cells. Symptoms include decreased urine output, fatigue, nausea and fluid retention. Treatment involves treating the underlying cause, fluid management, and potentially dialysis. Chronic renal failure (CRF) is the gradual, permanent loss of kidney function over months or years due to conditions like diabetes or hypertension. It leads to a buildup of waste products and imbalances in electrolytes. Management includes dietary modifications, medication, and long-term dialysis or transplant.
The document discusses disorders of the parathyroid glands and tetany. It notes that the parathyroid glands regulate calcium and phosphate levels and vitamin D metabolism. Disorders can cause hypercalcemia or hypocalcemia. Hypercalcemia symptoms include polyuria and renal problems. Hypocalcemia can cause tetany with muscle spasms. Primary causes, clinical features, investigations, and management are described for various parathyroid disorders including primary hyperparathyroidism and hypoparathyroidism. Tetany is defined as muscle spasms caused by parathyroid dysfunction and low calcium levels.
1) Fluid and electrolyte management is paramount for surgical patients as changes can occur pre, intra, and post operatively due to various factors.
2) Sodium and potassium disturbances are common and can cause issues in multiple body systems if not properly managed.
3) Treatment for abnormalities involves identifying the cause, restoring fluid and electrolyte deficits or excesses slowly and carefully based on symptoms and monitoring to prevent further complications.
Body Fluid and Compartments | DR RAI M. AMMAR | ALL MEDICAL DATA
by DR RAI M. AMMAR
www.facebook.com/drraiammar
www.twitter.com/drraiammar
www.instagram.com/drraiammar
www.linkedin.com/in/drraiammar
www.medicall.com.pk/blog/auther/drraiammar/
For Any Book or Notes Visit Our Website:
www.allmedicaldata.wordpress.com
www.drraiammar.blogspot.com
YOUTUBE CHANNEL :
https://www.youtube.com/channel/UCu-oR9V3OdFNTJW5yqXWXxA
ANY QUESTION ??
Get in touch with us at Any of the Above Social Media or Email at
drraiammar@gmail.com
allmedicaldata@gmail.com
This document provides an overview of fluid therapy and electrolyte disturbances. It discusses the basic physiology of body fluids, including total body water content and distribution. It then covers various electrolyte abnormalities like hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypomagnesemia, and hypermagnesemia. It also addresses acid-base balance disturbances and different intravenous fluid options for fluid resuscitation and maintenance.
The document discusses various topics related to renal alterations, electrolyte disturbances, intravenous fluid therapy, and neurological alterations. It provides objectives, definitions, signs and symptoms, causes, and treatments for various conditions including acute renal failure, electrolyte imbalances, intravenous fluid types, and more. The document is an educational review intended to enhance understanding of critical care nursing concepts.
1. A 52-year-old male presented with loose stools and vomiting for 4 days. Examination found hypokalemia.
2. ECG showed ST segment depression in V3-V6 and prominent U waves, consistent with changes seen in hypokalemia.
3. The patient was diagnosed with hypokalemia likely caused by gastrointestinal potassium losses from diarrhea, as indicated by his symptoms and laboratory findings. Treatment involved potassium supplementation and treatment of the underlying condition causing the diarrhea.
The document provides information about fluid and electrolyte balance. It discusses the distribution and composition of body fluids, normal fluid exchange, and electrolyte disturbances including hypovolemia, hypervolemia, hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypomagnesemia, and hypermagnesemia. It also covers parenteral fluid therapy including intravenous fluids, methods of calculating fluid transfusion rates, and management of fluid balance in surgical patients.
This document summarizes renal function tests and urine analysis. It describes the anatomy and function of the nephron, steps in urine formation, and normal ranges for physical and chemical urine tests including volume, color, odor, specific gravity, pH, creatinine, BUN, electrolytes, glucose, protein, and ketones. It discusses clinical implications of abnormal test values and interfering factors. Macroscopic urine examination for casts and cells is also covered, in addition to exogenous markers of glomerular filtration rate like inulin and iothalamate clearance tests.
1) An 85-year-old woman was hospitalized for severe anemia with a hemoglobin of 3 g/dL.
2) A 76-year-old man seen for forgetfulness and difficulty walking was found to have peripheral neuropathy and anemia with hypersegmented neutrophils on blood smear.
3) A 16-year-old female with autoimmune hepatitis developed anemia with heavier menses and petechiae; bone marrow showed mild dyserythropoiesis and hypocellularity.
The patient is a 40-year-old male who presented with weakness in both the upper and lower limbs for 3 days. Laboratory tests showed hypokalemia, metabolic alkalosis, hypomagnesemia, and increased urinary excretion of potassium, sodium, and chloride. Based on these findings, the nephrologist diagnosed the patient with Gitelman's syndrome, a genetic disorder characterized by loss of potassium, sodium, magnesium, and chloride in the urine.
This document provides an overview of calcium metabolism and disorders. It discusses:
1. The essential biochemical functions of calcium in muscle contraction, nerve impulse transmission, hormone secretion, and enzyme activation.
2. How calcium levels are tightly regulated by parathyroid hormone, calcitriol (vitamin D), and calcitonin through effects on intestinal absorption, renal excretion, and bone resorption.
3. Common calcium metabolism disorders like hypercalcemia and hypocalcemia, their causes, symptoms, and treatment. Primary hyperparathyroidism is the most common cause of hypercalcemia.
This document discusses the signs and symptoms of dehydration at different levels of severity based on percentage of weight loss. Mild dehydration is defined as a weight loss of less than 5% in infants and 3% in older children. Moderate dehydration involves a 5-10% weight loss in infants and 3-6% in older children. Severe dehydration is indicated by over 10% weight loss in infants and over 6% in older children. The document provides guidelines for fluid resuscitation and correction of fluid deficits based on the level of dehydration. It also discusses various causes, signs, and treatment approaches for electrolyte imbalances including hyponatremia, hypernatremia,
Similar to A Short Presentation on Hypercalcaemia (20)
1. Brown-Séquard syndrome was first described in 1850 based on observations of machete injuries in sugar cane farmers, with key features being ipsilateral motor paralysis and mixed sensory loss below the level of the spinal cord lesion.
2. Understanding the anatomy of ascending and descending spinal tracts is important for explaining the clinical features of Brown-Séquard syndrome and other spinal cord injuries.
3. Injuries can disrupt motor or sensory tracts differently, causing varying neurological deficits depending on whether the lesion involves upper or lower motor neurons.
The document discusses several inflammatory arthropathies known as spondylarthropathies. They are commonly associated with the HLA B27 gene and involve entheses, synovium, and the spine. Major types include ankylosing spondylitis, psoriatic arthropathy, reactive arthritis, and enteropathic arthritis. They often present with enthesitis, uveitis, and spondylitis and are treated with NSAIDs, DMARDs, anti-TNF drugs, or surgery depending on the specific condition and symptoms.
Lung cancer is classified into two main types - non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC). NSCLC makes up about 80% of cases and can be further divided into squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. SCLC accounts for 10-15% of lung cancers and grows more quickly. The main symptoms are cough, chest pain, and coughing up blood. Risk factors include smoking, asbestos exposure, and radiation exposure. Diagnosis involves tests such as sputum analysis, biopsies, CT scans, and PET scans to determine the cancer type and stage. Treatment options depend on the cancer type and stage but may include surgery, chemotherapy
Eczema herpeticum is a potentially life-threatening herpes infection that occurs when herpes simplex virus infects disrupted skin in patients with pre-existing skin conditions like eczema or atopic dermatitis. It presents with clusters of vesicles and punched-out erosions that spread and become hemorrhagic and crusted. Diagnosis involves identifying characteristic lesions along with fever and pain, and can be confirmed with tests like Tzanck smear, viral culture, or antibody testing. Aggressive treatment with IV acyclovir is required to prevent complications like herpes keratitis, which can lead to blindness. Early recognition and effective antiviral therapy are important given the potential severity of eczema her
The vagus nerve connects organs in the neck and below to the brainstem. It has both sensory and motor functions and helps control the heart rate, digestion, and other involuntary processes. Stimulation of the vagus nerve has been shown to reduce seizures, experimental pain, and inflammation, and may help treat conditions like epilepsy, obesity, and heart disease. Damage to the vagus nerve or its connections in the brainstem can impact swallowing, heart rate variability, and level of consciousness.
Poor water and sanitation are responsible for a huge global burden of disease, with contaminated water alone contributing to about 2.4 million preventable deaths per year, mainly in children. While progress has been made in increasing access to safe water and improved sanitation, current rates of progress will not meet the Millennium Development Goal targets. Water and sanitation remain a low priority on international development agendas despite their importance for health and achieving the MDGs. Coordinated efforts are still needed to address this critical issue.
This document discusses medical student electives in developing countries. It notes potential benefits like exposure to rare diseases and personal growth, but also flags ethical issues. Electives could exploit local health systems and raise false expectations. They may perpetuate neo-colonial practices by benefiting students and health systems in wealthy countries more than local populations. The document also examines how non-governmental organizations can undermine public health systems and calls for electives to minimize harm, respect local needs, and establish long-term exchange programs to provide mutual benefit.
This document provides an overview of global health by defining key terms, outlining major players and organizations, and summarizing the history and evolution of the field from 1945 to the present day. It describes how global health has shifted from a focus on infectious disease control to addressing social determinants of health and health issues that transcend national borders. Major milestones discussed include the founding of the UN and WHO, the Alma-Ata Declaration, structural adjustment policies, the Millennium Declaration and MDGs, debt relief campaigns, and the establishment of the Global Fund. The summary highlights the ongoing tension between disease-specific and comprehensive primary healthcare approaches.
The document discusses how international organizations like the WTO and treaties it has established like TRIPS and GATS impact healthcare. The WTO aims to liberalize trade and its dispute process enforces agreements. TRIPS established intellectual property standards that require drug patenting, raising prices. Some countries like Brazil and South Africa have issued compulsory licenses to produce cheaper generics, facing opposition from pharmaceutical companies but helping improve access to treatment.
Global health examines influences on health across borders, including issues like globalization, poverty, and human rights. It draws from multiple disciplines. Globalization refers to reducing barriers between countries, leading to increased trade, investment, and communication. This has effects like economic growth but also rising inequalities. Agreements like TRIPS have increased pharmaceutical patent protection globally, raising concerns about access to medicines, especially in developing countries. Networks of both commercial and civil society actors have been important in debates over balancing intellectual property with public health.
Migration of health care workers has both positive and negative effects on health. It reduces the availability of health services in source countries while increasing access in destination countries. This unequal distribution of health workers is driven by push factors like low pay and poor working conditions in source countries and pull factors like higher wages in destination countries. As a result, source countries experience worse health outcomes due to lack of health workers, while destination countries receive an indirect subsidy through the receipt and employment of trained medical professionals from poorer nations. Proposed policy responses aim to strengthen health systems in source countries, implement ethical recruitment practices, and foster partnerships between nations to promote more equitable health worker distribution.
Global institutions play major roles in health financing and policy. The key players discussed are the World Health Organization (WHO), World Bank, International Monetary Fund (IMF), and World Trade Organization (WTO). The WHO is the UN agency for health, working with 192 member states. The World Bank aims to reduce poverty through loans and policy advice to developing countries. The IMF promotes international monetary cooperation and provides temporary financial assistance. The WTO, formed in 1995, ensures trade flows freely through treaties and enforcement mechanisms, which some criticize can undermine public health systems.
Haemochromatosis is an autosomal recessive condition characterized by excessive iron accumulation in the body. It affects around 0.5% of Caucasians and usually presents in the 40s-50s with a triad of pigmentation, diabetes mellitus, and hepatomegaly. Diagnosis involves blood tests showing elevated serum iron, transferrin saturation over 50%, and elevated serum ferritin. Liver biopsy can confirm iron deposition and damage. Treatment aims to reduce iron stores through weekly venesection of 1 unit of blood for 6-12 months followed by maintenance venesection.
Ascites is an abnormal collection of fluid in the peritoneal cavity, commonly caused by portal hypertension due to cirrhosis. It results from sodium and water retention triggered by vasodilation and activation of the renin-angiotensin system, as well as increased hydrostatic pressure and transudation of fluid from the liver and spleen into the peritoneal cavity. Hypoalbuminemia due to decreased liver function also contributes by reducing plasma oncotic pressure. Spironolactone is used as treatment as it is an aldosterone antagonist. Management involves dietary sodium restriction, diuretics, stopping alcohol, monitoring for complications, and procedures such as paracentesis or shunts.
The liver has two lobes, separated by veins, and is divided into sections supplied by individual blood vessels. Blood flows through hepatic arteries and portal veins into sinusoids, where waste is filtered by Kupffer cells in the space of Disse before draining into hepatic veins. The liver performs many functions including synthesizing proteins, metabolizing carbohydrates and lipids, and detoxifying hormones and drugs. Liver function can be assessed through blood tests of enzymes and proteins.
Antidepressants such as SSRIs, TCAs, and MAOIs work by increasing levels of serotonin, norepinephrine, or both in the brain. SSRIs are generally first-line treatment and safer in overdose than TCAs, but TCAs may be better for severe depression. Both classes of drugs can cause side effects like dry mouth, nausea, and sexual dysfunction. Antidepressants may take 10-20 days to work and should be continued for at least 6 months after symptoms improve to prevent relapse. Combining certain antidepressants can be dangerous due to increased serotonin levels.
Gout is caused by deposition of uric acid crystals in the joints, which leads to acute inflammation. It typically presents as sudden severe pain, swelling and redness in one joint, most commonly the big toe. Diagnosis is made based on symptoms and identification of crystals in joint fluid under polarized microscopy. Treatment involves medications to reduce symptoms during acute attacks as well as long-term drugs like allopurinol or probenecid to lower uric acid levels and prevent future episodes. Without treatment, gout can progress to a chronic stage with multiple joint involvement and growth of tophi deposits in the tissues.
Review of orthopaedic services: Prepared for the Auditor General for Scotland...meducationdotnet
1. Orthopaedics is a large specialty that treats musculoskeletal conditions through surgery, medication, and rehabilitation. It accounts for a significant portion of NHS spending and activity in Scotland.
2. Waiting times for orthopaedic services have reduced in recent years through changes to service delivery and additional funded activity. However, further improvements to meet 18-week referral targets will be challenging to sustain.
3. There is variation in orthopaedic efficiency across Scotland that is not fully explained by resources or procedures. The report finds opportunities to use existing resources more efficiently through measures like increasing day surgery and reducing hospital length of stay.
This document discusses the use of muscle relaxants in anesthesia and the potential role of sugammadex as a reversal agent. It provides background on why muscle relaxants are used, types of muscle relaxants, and current problems with reversal agents. It then summarizes research on sugammadex, which appears to be a more effective reversal agent than anticholinesterases, allowing faster recovery from neuromuscular blockade. Sugammadex may allow safer use of muscle relaxants and replace agents like suxamethonium, but economic factors will also influence its adoption.
This document contains a series of slides related to ophthalmology. It tests the reader's knowledge on topics like visual acuity measurements, refractive errors, eye abnormalities, causes of vision loss, and eye examination techniques. The slides include images showing conditions like cataracts, glaucoma, retinal detachments, and more. Key details are provided about diagnoses, symptoms, investigations, and treatments.
2. Case Study
49 ♂
PC- presented to GP about rash on face &
snoring
Investigations revealed hypercalcaemia – 3.2mmol/L
Came to A&E at HRI
3. Clerking in AAU
3-4 month history of abdominal discomfort
Elbow pain
2-3 month history of ↑ fatigue
Polydipsia & ↑ fluid intake
4. Negative findings
No change in mood
No excessive dietary calcium
No unintentional weight loss
No change in appetite
No fever
No night sweats
No loin-groin colicky pain
No PR bleeding, haematuria, haemoptysis
No chest pain or palpitations
No SOB
No vomiting & nausea
No urinary symptoms
No bowel symptoms
5. PMH – nil
Drugs – nil
Allergies – nil
SH – non smoker
alcohol – 5 units a week
lives with wife & two children
very active (runner), good diet
PHD in engineering – works at Kimberley Clarke
FH – dad died of multiple myeloma age 62
6. Examination
General – comfortable at rest
alert & orientated
observations stable
no signs of dehydration
no signs of anaemia
• Chest - NAD
• HS – I + II + 0
• Abdomen – NAD
• Neurological – NAD
• Elbows – no bony tenderness
not red, hot, swollen
FROM
pain on wrist
extension
9. BCP
Na – 140
K – 4.6
Cl – 107
Bicarb – 27
Urea – 6.5
Creatinine – 96
Ca – 3.31 ↑
Adj Ca – 3.26 ↑
Ph – 0.64 ↓
Bil – 27 ↑
AP – 139
ALT – 60 ↑
TP – 73
Al – 46
TSH - normal
Amylase – normal
PSA – normal
Coeliac screen – negative
PTH – 403 ↑
10. ECG – NAD
CXR – NAD
Abdominal USS – NAD
Management
Fluids
Bisphosphonates
Treat cause
11. The role of calcium
Formation & maintenance of bones & teeth
Role in blood clotting
Hormone release
Muscle contraction
Nerve & brain function
Enzymatic reactions
12.
13. The importance of vitamin D
Essential for calcium absorption in the small
intestine
Cholesterol
Cholecalciferol
Calcidiol
Calcitrol
Skin
Liver
Kidney & peripherally
Dietary
calcium
15. Hypercalcaemia
“The presence in the blood of an abnormally high
concentration of calcium”
Oxford concise medical dictionary 2007
Mild hypercalcaemia = 2.6 – 2.9 mmol/L
Moderate hypercalcaemia = 3.0 – 3.4 mmol/L
Severe hypercalcaemia = greater than 3.4 mmol/L
20. Hypercalcaemia
Albumin raised Albumin normal or low
Urea raised Urea normal Phosphate low
or normal
Phosphate raised
or normal
Dehydration Cuffed specimen Urea normal
Primary or tertiary
hyperparathyroidism
Alk Phos normalAlk Phos raised
Bone mets
Sarcoidosis
Thyrotoxicosis
Myeloma
Vitamin D excess
Sarcoidosis
Milk alkali syndrome
22. Management
Urgent treatment if calcium
> 3.5mmol/L
↓ consciousness or confusion
Hypotension
Severe dehydration causing pre-renal failure
IV fluids
Diuretics
IV bisphosphonates
Treat the cause
3-4 month history of abdominal discomfort. Mainly bloating across the whole of the abdomen, radiating round the left side. Possible link to white bread – improved when cut out of diet. Not very severe, more discomfort than pain. Worse in the morning. No nausea & vomiting. No diarrhoea or constipation. No steatorrhea. No RUQ pain.
1 month history of elbow pain. Worse on movement, not present at rest. No worse at night. Possible tennis elbow. Worse on wrist flexion. No long bone pain
Increased fatigue for which no known cause. Not noted any pallor, SOB. No decrease in appetite or weight loss.
Has noticed he has been thirstier and drinking more recently
First diagnosis because few other symptoms which would suggest other causes. For example, GI discomfort with coeliac, weight loss & anaemia with malignancy, signs of thyrotoxicosis, sarcoidosis & pancreatitis. Also the most common cause in someone his age.
Possible due to there being an increased risk with primary relatives, however unlikely as no obvious anaemia, weight loss, appetite change.
Unlikely as no systemic symptoms & low risk factors however you would want to rule out
Possible although does not fit with polydipsia
Granulomatous disease. Sarcoidosis, TB, inflammatory lung disease.
Possible however usually does not have calcium levels that high. Diagnosis of exclusion.
Normal Hb makes malignancy less likely.
Normal WCC count makes inflammatory disease less likely
Electrolytes & urea are normal which doesn’t suggest dehydration.
Calcium & phosphate exist in a delicate balance.
Phosphorus is also stored in bones & teeth.
Phosphate is excreted by PTH
Main component
Co-factor in the coagulation cascade. Activates protein kinase C. Also rewuired for prothrombinase function
Ca2+ Channels
Co-factor in many enzymatic reactions
This system is mainly controlled by PTH, released from the parathyroid gland. When calcium levels are low in the blood, PTH is released which triggers more Ca2+ to be reabsorbed in the kidneys and bone breakdown to release Ca2= into the blood. This stimulates the kidneys to produce more vitamin D which increases calcium absorption from the gut. Also important to mention that the kidneys have their own homeostatic mechanism with calcium receptors that monitor levels & adapt renal reabsorption/excretion accordingly.
When the calcium is mildly elevated the thyroid stops releasing PTH & this is generally enough to stop levels rising.
However when levels are especially high the thyroid gland releases calcitonin which stimulates osteoblasts to absorb Ca2+ back into bone and increases excretion in the kidneys.
This is a simplified lifecycle for vitamin D.
Vitamin D is essential for the absorption of calcium from the gut. It basically binds to vitamin D receptors in the gut which stimulates absorption.
The body can synthesise vitamin D itself from cholesterol using UV B waves from sunlight. This then creates cholecalciferol. This is also the form in which most of our dietary vitamin D is.
In the liver Cholecalciferol is converted in calcidiol (also known as calcifediol (INN), 25-hydroxycholecalciferol, or 25-hydroxyvitamin D—abbreviated 25(OH)D; and which is the specific vitamin D metabolite that is measured in serum to determine a person's vitamin D status)
The majority of this is then converted to calcitrol (active vitamin D hormone) in the kidneys.
A small amount of cacidiol circulates in the blood & is converted to active vitamin D in the peripheries where it is needed. It performs functions such as proliferation, differentiation & apoptosis of cells, especially in areas of inflammation.
The role of vitamin D includes the regulation of Ca2+ by increasing absorption from the gut, and promoting resorption from bone by increasing the number of osteoclasts.
Almost 50% of calcium in the blood is bound to proteins. Corrected calcium takes into account the changes in calcium there may be if the amount of albumin is abnormal. Eg, if less albumin more may be free giving the impression of hypercalcaemia
Often asymptomatic in the early stages.
Has to be quite severe to cause symptoms.
J waves or Osborn waves – positive deflection at the J point
Primary hyperparathyroidism -Going to discuss in more detail
Malignancy - Cause of hypercalcaemia is bone breakdown. Metastases – most commonly breast, kidney, lung, thyroid, prostate, ovary, colon. Paraneoplastic symdrome – non small cell lung cancer, ovarian cancer, phaeochromocytoma. Also cancer without mets can produce hypercalcaemia The mechanism for hypercalcaemia in almost all people with cancer is secretion (by cancer cells) of parathyroid hormone-related peptide (PTHrP) and other circulating factors. These patients have about 2-3 months.
Adrenal gland failure – enhanced absorption of calcium in the gastrointestinal tract, hemoconcentration, decreased GFR from volume contraction and increased complexing and protein binding of calcium. A component of decreased renal excretion may contribute. Loss of the antagonistic effects of glucocorticoids on calcium absorption and bone mobilization, together with dehydration.
Calcium excess in diet. Sources of calcium – dairy products, leafy greens, eggs, legumes, nuts & whole grains. This also includes milk alkali syndrome – too much milk in diet or medical products like calcium carbonate, gaviscon.
Dehydration - Due to less fluid in the blood so relatively higher ca2+ concentration
Iatrogenic –
Thiazide diuretics can cause hypercalcaemia by increasing the renal tubular reabsorption of calcium, but other mechanisms are postulated. Hypercalcaemia is usually mild.
Often, the underlying cause is found to be primary hyperparathyroidism, with hypercalcaemia only worsened by the thiazide.
Lithium causes hypercalcaemia by altering the parathyroid feedback threshold, stimulating parathyroid hypertrophy (with long-term use), and reducing renal calcium clearance.
Most people taking lithium have a slight increase in serum calcium concentration within 4 weeks of starting treatment, but the level is usually within the normal range and returns to baseline when treatment is discontinued.
Thyrotoxicosis – usually mild hypercalcaemia. T3 is essential for normal bone growth & bone metabolism. It stimulates bone formation directly through T3 receptors in osteoblasts. Also stimulates bone resorption by osteoclasts probably secondary through osteoblasts. In thyrotoxicosis accelerated bone resorption results in hypercalcaemia in the blood
Inflammation - Eg. sarcoidosis, TB, leprosy, histoplasmosis, & types of granuloma. Tissue injury causes an ectopic production of 1,25-dihydroxyvitamin D3 (calcitriol), which causes vitamin D toxicity.
Renal failure- Due to tertiary hyperparathyroidism. In chronic renal failure you get hypocalcaemia because the kidney is important in producing vit D, this creates secondary hyperparathyroidism as PTH release increases to try to increase calcium. The parathyroid hypertrophies. After a while the hypertrophied parathyroid starts to release excess parathyroid hormone autonomously which becomes unregulated & you get hypercalcaemia.
Vitamin D excess – increased vitamin D causes increased calcium ingestion from the gut.
FBHH – loss of function mutation in the CASR gene which encodes a calcium sensing receptor in the parathyroid & kidney. Percieved lack of calcium leads to high levels of parathyroid hormone and decreased excretion by the kidneys. Rare autosomal dominant disorder. Characterised by asymptomatic hypercalcaemia & a normal PTH.
Pagets = increased bone turnover
Immobilization- Immobilization can lead to hypercalcaemia in people with accelerated bone turnover, due to enhanced osteoclast activity and diminished osteoblast activity ('uncoupling' of bone cell activity).
People with Paget's disease, cancer, or primary or secondary hyperparathyroidism are at risk.
Primary hyperparathyroidism -Going to discuss in more detail
Malignancy - Cause of hypercalcaemia is bone breakdown. Metastases – most commonly breast, kidney, lung, thyroid, prostate, ovary, colon. Paraneoplastic symdrome – non small cell lung cancer, ovarian cancer, phaeochromocytoma. Also cancer without mets can produce hypercalcaemia The mechanism for hypercalcaemia in almost all people with cancer is secretion (by cancer cells) of parathyroid hormone-related peptide (PTHrP) and other circulating factors. These patients have about 2-3 months.
Adrenal gland failure – enhanced absorption of calcium in the gastrointestinal tract, hemoconcentration, decreased GFR from volume contraction and increased complexing and protein binding of calcium. A component of decreased renal excretion may contribute. Loss of the antagonistic effects of glucocorticoids on calcium absorption and bone mobilization, together with dehydration.
Calcium excess in diet. Sources of calcium – dairy products, leafy greens, eggs, legumes, nuts & whole grains. This also includes milk alkali syndrome – too much milk in diet or medical products like calcium carbonate, gaviscon.
Dehydration - Due to less fluid in the blood so relatively higher ca2+ concentration
Iatrogenic –
Thiazide diuretics can cause hypercalcaemia by increasing the renal tubular reabsorption of calcium, but other mechanisms are postulated. Hypercalcaemia is usually mild.
Often, the underlying cause is found to be primary hyperparathyroidism, with hypercalcaemia only worsened by the thiazide.
Lithium causes hypercalcaemia by altering the parathyroid feedback threshold, stimulating parathyroid hypertrophy (with long-term use), and reducing renal calcium clearance.
Most people taking lithium have a slight increase in serum calcium concentration within 4 weeks of starting treatment, but the level is usually within the normal range and returns to baseline when treatment is discontinued.
Thyrotoxicosis – usually mild hypercalcaemia. T3 is essential for normal bone growth & bone metabolism. It stimulates bone formation directly through T3 receptors in osteoblasts. Also stimulates bone resorption by osteoclasts probably secondary through osteoblasts. In thyrotoxicosis accelerated bone resorption results in hypercalcaemia in the blood
Coeliac disease - Calcium & vitamin D malabsorption leading to secondary hyperparathyroidism, may cause osteopenia & bone breakdown hence increased blood calcium.
Inflammation - Eg. sarcoidosis, TB, leprosy, histoplasmosis, & types of granuloma. Tissue injury causes an ectopic production of 1,25-dihydroxyvitamin D3 (calcitriol), which causes vitamin D toxicity.
Renal failure- Due to tertiary hyperparathyroidism. In chronic renal failure you get hypocalcaemia because the kidney is important in producing vit D, this creates secondary hyperparathyroidism as PTH release increases to try to increase calcium. The parathyroid hypertrophies. After a while the hypertrophied parathyroid starts to release excess parathyroid hormone autonomously which becomes unregulated & you get hypercalcaemia.
Vitamin D excess – increased vitamin D causes increased calcium ingestion from the gut.
FBHH – loss of function mutation in the CASR gene which encodes a calcium sensing receptor in the parathyroid & kidney. Percieved lack of calcium leads to high levels of parathyroid hormone and decreased excretion by the kidneys. Rare autosomal dominant disorder. Characterised by asymptomatic hypercalcaemia & a normal PTH.
Pagets = increased bone turnover
Immobilization- Immobilization can lead to hypercalcaemia in people with accelerated bone turnover, due to enhanced osteoclast activity and diminished osteoblast activity ('uncoupling' of bone cell activity).
People with Paget's disease, cancer, or primary or secondary hyperparathyroidism are at risk.
Cuffed blood sample – leaving the tourniquet on too long can cause hyperkalaemia, hypercalcaemia & lactic acidosis
These long term complications of hypercalcaemia are uncommon today.
Nephrocalcinosis = calcium deposits in the kidney
IV fluids – Normal saline 0.9%> Aim for 3-6L/24hrs depending on fluid status, urine output & cardiac function.
Diuretics – once patient is rehydrated continue saline infusion & add frusemide 40mg every 2-4hrs. Monitor carefully. Be aware k+ & Mg2+ which may fall rapidly with rehydration & fursemide.
If this fails:-
Bisphosphonates- pamidronate at 30-60mg IV over 4-6hrs. Works by inhibiting osteoclasts. Ca2+ levels begin to fall after 48hrs & remain suppressed for 14 days.
Then treat the cause & it will resolve
Up to 21/1000 post menopausal women
Multiple endocrine neoplasia
Famillial – average age of presentation of 22yrs. Autosomal dominant inheritance. Asymptomatic.
In all cases the disease is idiopathic however there has been shown to be increased risk with radiation exposure. See after the chenoble disaster.
Excess PTH causes hypercalcaemia by increasing renal calcium reabsorption and mobilizing calcium from bone. It also indirectly increases intestinal calcium absorption, by increasing synthesis of serum 1,25-dihydroxyvitamin D3 (calcitriol, the active form of vitamin D3
Bloods - sensitivity of 60%-80% and a specificity of approximately 90% for primary hyperparathyroidism.[
Infusion - sensitivity of 100% and a specificity of 93% in detecting primary hyperparathyroidism, with a confidence interval of 80% to 100%
If it is one gland then it is easy. If it is all 4 3.5 glands are taken out.
Post surgical complications include hypocalcaemia as the majority of the Ca2+ and phosphate is reabsorbed back into the bone. The parathyroid gland takes time to become resensitised so also hypoparathyroidism which is often transient but can become long term requiring supplements.
Guidelines for whom surgery should be offered were produced by a National Institutes of Health (NIH) Workshop on Asymptomatic Primary Hyperparathyroidism in 2002:[7]
Serum albumin-adjusted calcium greater than 0.25 mmol/L above the upper limit of local laboratory reference range.
24 hour total urinary calcium excretion greater than 10 mmol (400mg).
Creatinine clearance reduced by 30% or more.
Bone mineral density T score less than -2.5 (at any site).
Age younger than 50 years.
Patient request; adequate follow-up unlikely.
HRT & raloxifene may be used in post-menopausal women. They have been shown to reduce calcium levels as well as improve bone density.[1] However, because of the risks associated with oestrogen replacement, it should not be used purely to treat primary hyperparathyroidism.[2]
Bisphosphonates (particularly alendronate) may be a useful treatment.[1]
Cinacalcet reduces both serum calcium and PTH levels and raises serum phosphorus. Cinacalcet does not, however, reduce bone turnover or improve bone mineral density.[9]